T1	Treatment 341 511	tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders.
T2	Treatment 610 625	tamoxifen alone
